RedHill Biopharma (RDHL) Share-based Compensation (2012 - 2023)

RedHill Biopharma (RDHL) has reported Share-based Compensation for 12 consecutive years, with $705000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Share-based Compensation rose 14.08% year-over-year to $705000.0 in Q2 2023; TTM through Jun 2023 was $3.6 million, a 48.5% decrease from a year earlier, with the FY2025 full-year figure at $457000.0, down 31.28% from the prior year.
• Share-based Compensation was $705000.0 for Q2 2023 at RedHill Biopharma, up from $144000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $5.3 million in Q2 2021 and troughed at $144000.0 in Q1 2023.
• A 5-year average of $1.3 million and a median of $904500.0 in 2019 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 746.55% in 2021 and tumbled 93.76% in 2023, its largest moves.
• Over 5 years, Share-based Compensation stood at $749000.0 in 2019, then soared by 44.46% to $1.1 million in 2020, then surged by 73.29% to $1.9 million in 2021, then plunged by 39.36% to $1.1 million in 2022, then tumbled by 37.99% to $705000.0 in 2023.
• The last three Share-based Compensation figures came in at $705000.0 (Q2 2023), $144000.0 (Q1 2023), and $1.1 million (Q4 2022), per Business Quant data.